- Exebacase added to standard-of-care (SOC) antibiotics yielded a higher clinical responder rate than antibiotics alone in a subgroup of patients with methicillin-resistant staphylococcus aureus (MRSA) bacteremia.
- Exebacase reduced length of stay, 30-day readmissions in this phase 2 study.
- Results support phase 3 trial.
Why this matters
- MRSA has high social and economic costs.
- Lysins like exebacase are first in class and synergistic with conventional antibiotics, with a low propensity for resistance.
- Randomized, double blind, placebo-controlled, superiority design phase 2 study in adults with MRSA bacteremia, including endocarditis.
- Study compared exebacase plus SOC antibiotics with antibiotics alone in the modified intention-to-treat population (71 patients on exebacase+SOC vs 45 patients on antibiotics alone).
- Primary endpoint: clinical responder rate at day 14.
- In the prespecified MRSA subgroup, exebacase (n=27) resulted in a 42.8% higher responder rate at day 14 vs antibiotics alone (n=16).
- Exebacase was associated with reduced hospital length of stay by 4 days (median stay, 6 days for exebacase vs 10 for antibiotics) and reduced readmissions.
- Exebacase was safe and well-tolerated.
- Presented without peer review at a conference.